Home/Pipeline/Aza Indenoisoquinolines

Aza Indenoisoquinolines

Oncology

Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Active

Company

Gibson Oncology

About Gibson Oncology

Gibson Oncology is a private, pre-revenue biotech founded in 2018, headquartered in Nashville, TN, with a significant operational presence in Miami, FL. Its lead asset, LMP744, has received FDA Orphan Drug Designation for glioblastoma and is entering a Phase II trial in collaboration with the NIH, leveraging its unique dual Top1/cMYC inhibition and ability to cross the blood-brain barrier. The company's broader pipeline includes additional licensed compounds (LMP400, LMP776) and an internally discovered oral class of Aza Indenoisoquinolines, targeting homologous recombination deficient cancers and offering potential synergy with PARP inhibitors.

View full company profile

Therapeutic Areas

Oncology Glioblastoma Brain Cancer

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active